免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据,仅供一般参考,不构成医疗建议、诊断、治疗建议或投资建议。

临床试验

Oral Colloidal Silicon Dioxide Added to Routine Treatment for Acute Urticaria in the Emergency Department

NCT:NCT07866092 · COMPLETED

NCT编号NCT07866092
状态COMPLETED
开始日期2026-08-24
完成时间2026-10-01
SponsorAnkara Etlik City Hospital (OTHER_GOV)
First posted
Last updated

简要摘要

The goal of this observational study is to learn whether adding a single oral dose of colloidal silicon dioxide, an enterosorbent, to routine emergency department treatment is associated with faster early improvement in adults with acute urticaria. The main question it aims to answer is: Is the change in urticaria activity over the first 2 hours different in patients who receive colloidal silicon dioxide in addition to intravenous pheniramine compared with patients who receive intravenous pheniramine alone? Treatment is chosen by the treating emergency physician as part of routine care, before patients are approached for the study. Participants are assessed before treatment and at 1 and 2 hours, and are contacted by telephone at 24 hours.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态,请参阅官方记录。

↑